| Impact of the COVID-19 pandemic on hepatitis C outcomes at a health-system specialty pharmacy MP Cooper, H Foley, D Damico, M Wright, C Rhudy, A Schadler, T Platt Journal of Managed Care & Specialty Pharmacy 28 (6), 667-672, 2022 | 1 | 2022 |
| Impact of the COVID-19 pandemic on hepatitis C outcomes at a health-system specialty pharmacy M Wright, C Rhudy, A Schadler, T Platt My disease is not “just hair loss”, 667, 2022 | | 2022 |
| HEPATITIS C TREATMENT UPTAKE IN TELEMEDICINE MODEL IS AT LEAST EQUAL TO FACE-TO-FACE OUTPATIENT CLINIC MODEL N Hooman, AA Miller, M Wright, M Starks-Baker, S Arnold, J Rosenau HEPATOLOGY 74 (6), 1417A-1417A, 2021 | | 2021 |
| MEDICAID POLICY OF REQUIRING DOCUMENTATION OF HEPATITIS C CHRONICITY FOR APPROVAL OF HCV MEDICATIONS RESULTS IN LOW TREATMENT UPTAKE, DELAYED TREATMENT, AND LOSS TO FOLLOW UP. N Hooman, C Hammill, A Miller, M Starks-Baker, M Wright, J Weiss, ... HEPATOLOGY 74, 568A-568A, 2021 | | 2021 |
| CLINICAL SIGNIFICANCE OF DETECTABLE HCV RNA DURING AND AFTER TREATMENT WITH 8 WEEKS COURSE OF GLECAPREVIR/PIBRENTASVIR. B Ismail, T Wolford, K Parker, M Wright, K Fischer, K Benrajab, J Rosenau HEPATOLOGY 70, 904A-905A, 2019 | | 2019 |
| Treatment Uptake in Hepatitis C virus Infected Patients in Central and Eastern Kentucky RG Racho, M Abdelwadoud, JA Brown, PA Santos, CB Kuns-Adkins, ... Gastroenterology 152 (5), S1076, 2017 | | 2017 |
